Source: Virtual Congress 2021 – Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease



Rating:

Share or cite this content

Citations should be made in the following way:
S. Sharma (Woking Surrey, United Kingdom), F. Ali (Woking Surrey, United Kingdom), S. Sujoy (Woking Surrey, United Kingdom), K. Jola (Woking Surrey, United Kingdom). Interferon gamma (IFN?) pathway deficiency and severe NTM disease. 3086

Member's Comments

No comment yet.

Related content which might interest you: What is the best test to detect latent tuberculosis infection in sarcoidosis patients? – Comparison between two commercially available interferon gamma release assays Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Tuberculin skin test or interferon gamma release assay - How to detect latent tuberculosis infection in sarcoidosis patients? Source: International Congress 2015 – Sarcoidosis: clinical Year: 2015 Interferon gamma release assays based on M. tuberculosis-specific antigens (IGRAs) in sarcoidosis patients Source: International Congress 2015 – Sarcoidosis: pathogenesis Year: 2015 Inhaled IFN-γ for persistent nontuberculous mycobacterial pulmonary disease due to functional IFN-γ deficiency Source: Eur Respir J 2004; 24: 367-370 Year: 2004 Aerosol delivery of an immunomodulator (interferon-γ 1b) within mouse lungs Source: International Congress 2015 – Interstitial lung diseases I Year: 2015 Significance of interferon gamma-inducible chemokines in pleural effusions Source: International Congress 2015 – Biomarkers in TB: immunology and physiology Year: 2015 Interferon gamma release assays in screening for tuberculosis – Can we use them in patients with sarcoidosis? Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 A combinatorial dual-immunoassay predicts reactivation risk for patients with previously incomplete treatment for latent tuberculosis infection Source: International Congress 2016 – Active and latent tuberculosis: biomarkers Year: 2016 Initiation of anti-TNF therapy within 3 weeks of LTBI treatment in patients with immune-mediated inflammatory diseases Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 Diagnosing latent tuberculosis in immunocompromised patients measuring blood IP-10 production capacity: An analysis of chronic renal faulire patients Source: International Congress 2015 – Screening strategies in TB Year: 2015 Evolution of previous sarcoidosis under type 1 interferons given for severe associated disease Source: Eur Respir J 2005; 25: 570-573 Year: 2005 TGF-β 1 suppresses IRF-1 expression in pulmonary fibroblasts and modulates its induction by IFN α and IFN γ Source: Annual Congress 2011 - Lung cell injury and repair Year: 2011 Interferon (-alpha, -beta, and -omega) receptor 2 (IFNAR2) is a prognostic biomarker for lung cancer Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer Year: 2011 CD8-response associates with active tuberculosis and TB2-tube response in the QuantiFERON-TB-Plus kit Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers Year: 2016 Genetic tendency for developing tuberculosis: 8 patients with IL-12 receptor β1 deficiency Source: Eur Respir J 2004; 24: Suppl. 48, 397s Year: 2004 Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: 496-504 Year: 2006 Lung expression of interleukin-13 (IL-13) and interferon gamma (IFNg) in emphysema in human Source: Eur Respir J 2002; 20: Suppl. 38, 584s Year: 2002 Treatment of Idiopathic pulmonary fibrosis with interferon beta - our experience in seven patients Source: Eur Respir J 2003; 22: Suppl. 45, 44s Year: 2003 HLA-DRB homozygosity negatively affects the Interferon gamma release assay response to Mycobacterium tuberculosis antigens Source: International Congress 2017 – Human susceptibility to tuberculosis Year: 2017 An evaluation of the use of a negative interferon gamma release assay for tuberculosis screening before TNF antagonist therapy Source: Eur Respir J 2014; 44: 1369-1372 Year: 2014